Revolution Medicines Q3 Earnings: Stellar Company And Drug, But The Market Knows It

Impact · against what's priced in

Strong initial Q3 revenue from RASONQUE's launch confirms commercial viability but fails to act as a catalyst because the market had already priced in the FDA approval and launch. With a $40B valuation, the stock remains stagnant as the market continues to discount expansion into NSCLC and further platform potential.

RVMD+0.00

Already priced in

The price assumes

FDA approval and commercial launch of daraxonrasib (RASONQUE) for metastatic pancreatic adenocarcinoma